MedTrace Logo

Population Pharmacokinetic - Pharmacodynamic Models of Chronic Disease Therapeutics for Smokers

NCT05126381 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2023-06-18

No results posted yet for this study

Summary

Purpose of study: Establishing population pharmacokinetic - pharmacodynamic models of chronic disease therapeutics for smoking patients to investigate the effects of gender, age, body weight, liver function, kidney function, nicotine, polycyclic aromatic hydrocarbon related metabolic enzymes and drug related metabolic enzymes gene polymorphism on steady-state drug concentration and efficacy in chronic smoking patients after taking drugs.

Object of study: Smoking and non-smoking patients taking levamlodipine besylate tablets or metformin sustained-release tablets.

Conditions

Interventions

BEHAVIORAL

Smoking

The Study contains patients who are allowed to smoke

BEHAVIORAL

non-somking

The Study contains patients who are not allowed to smoke

Sponsors & Collaborators

  • The Second Affiliated Hospital of Chongqing Medical University

    lead OTHER

Principal Investigators

  • Yu Xian · The Second Affiliated Hospital of Chongqing Medical University

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-13
Primary Completion
2024-04-30
Completion
2024-04-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05126381 on ClinicalTrials.gov